A Phase 2/3 Randomized, Openn-Label, Multi-center Study to Determine the Safety and Efficacy of Solithromycin in Adolescents (12 to17 years of age, inclusive) and Children (>- 2 months to < 12 years of age) with Suspected or Confirmed Community

Administered By

Awarded By

Contributors

Start/End

  • May 22, 2017 - May 23, 2018